Scarica l'app Stockscreener
96.95
1.65%
1.57
Dopo l'orario di chiusura:
96.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVTY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$95.38
Aprire:
$95.16
Volume 24 ore:
942.85K
Relative Volume:
0.80
Capitalizzazione di mercato:
$10.82B
Reddito:
$2.90B
Utile/perdita netta:
$239.11M
Rapporto P/E:
45.92
EPS:
2.1112
Flusso di cassa netto:
$492.45M
1 W Prestazione:
+3.17%
1M Prestazione:
+2.83%
6M Prestazione:
-1.34%
1 anno Prestazione:
+7.15%
Intervallo 1D:
$94.71
$97.01
Intervallo di 1 settimana:
$92.97
$97.26
Portata 52W:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Nome
Revvity Inc
Settore
Industria
Telefono
781-663-6900
Indirizzo
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
96.95 | 10.64B | 2.90B | 239.11M | 492.45M | 2.1112 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-12-09 | Iniziato | Goldman | Neutral |
| 2025-10-16 | Iniziato | Guggenheim | Neutral |
| 2025-05-01 | Aggiornamento | UBS | Neutral → Buy |
| 2025-01-10 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-15 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-07-08 | Iniziato | Leerink Partners | Outperform |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-01-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-05-23 | Ripresa | Goldman | Buy |
Mostra tutto
Revvity Inc Borsa (RVTY) Ultime notizie
Revvity stock: Analyst estimates & ratings - MSN
Revvity stock (US76155R1086): cancer test launch and steady demand keep diagnostics group in focus - AD HOC NEWS
Revvity declares $0.07 dividend - MSN
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity Stock: Analyst Estimates & Ratings - inkl
Revvity stock (US76155R1086): diagnostics specialist in focus after latest earnings and life-science - AD HOC NEWS
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity Inc. stock (US76155R1086): investors weigh latest earnings and diagnostics focus - AD HOC NEWS
There May Be Some Bright Spots In Revvity's (NYSE:RVTY) Earnings - 富途牛牛
Revvity's (NYSE:RVTY) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
Revvity stock (US76155R1086): Q1 earnings beat and guidance set the tone - AD HOC NEWS
Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearance - Sahm
Revvity stock (US76155R1086): FDA assay clearance, outlook to 2026 and fresh collaboration momentum - AD HOC NEWS
Can Revvity Expand Diagnostics Across the S&P 500 Index? - Kalkine Media
Revvity, Inc. (RVTY): Investor Outlook Reveals 20.94% Potential Upside In Healthcare Innovation - DirectorsTalk Interviews
Revvity stock (US76155R1086): steady diagnostics player after latest quarterly update - AD HOC NEWS
RVTY expands endocrine diagnostics with FDA-cleared testosterone assay - MSN
Revvity stock (US76155R1086): collaboration momentum and diagnostics focus after recent share move - AD HOC NEWS
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Revvity stock (US76155R1086): T. Rowe Price reports a 9% stake - AD HOC NEWS
FDA OKs Revvity’s Total Testosterone Assay - Medical Product Outsourcing
T. Rowe Price (RVTY) discloses 10.1M-share, 9.0% stake in Revvity - Stock Titan
(RVTY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
The Top 5 Analyst Questions From Revvity’s Q1 Earnings Call - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY) - The Globe and Mail
Revvity stock (US76155R1086): Q1 earnings beat with $1.06 EPS - AD HOC NEWS
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay - The Globe and Mail
BofA Securities Maintains Revvity(RVTY.US) With Hold Rating - Moomoo
Is Revvity stock underperforming the S&P 500? - MSN
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says U - GuruFocus
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says Undervalued - GuruFocus
Revvity stock (US76155R1086): FDA clearance for testosterone assay, Q1 earnings beat - AD HOC NEWS
Transcript : Revvity, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 09 - marketscreener.com
FDA Clears Revvity Total Testosterone Assay for Automated Testing - Clinical Lab Products
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution - Yahoo Finance
Revvity (RVTY) grows Q1 2026 sales to $711M while margins tighten - Stock Titan
Revvity stock (US76155R1086): Q1 earnings beat and analyst upgrade drive gains - AD HOC NEWS
Revvity (NYSE:RVTY) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity (RVTY) director Alexis Michas receives stock awards and reports indirect holdings - Stock Titan
REVVITY (RVTY) director granted new restricted stock unit awards - Stock Titan
Revvity (RVTY) director Michael Klobuchar receives new restricted stock unit grants - Stock Titan
Revvity (RVTY) director Frank Witney granted restricted stock unit awards - Stock Titan
Director Samuel R. Chapin receives stock awards at REVVITY (RVTY) with RSUs vesting in 2027 - Stock Titan
Revvity (RVTY) director Michel Vounatsos receives new restricted stock units - Stock Titan
Revvity (RVTY) director Michelle McMurry-Heath granted new RSU awards - Stock Titan
Equity grants add 2,280 shares to Revvity (RVTY) director’s stake - Stock Titan
Revvity (RVTY) Q1 2026 Earnings Transcript - AOL.com
Revvity stock (US76155R1086): Q1 beat and analyst upgrade spark gains - AD HOC NEWS
Mitsubishi UFJ Asset Management Co. Ltd. Trims Stake in Revvity Inc. $RVTY - MarketBeat
Revvity earnings: What to look for from RVTY - MSN
Revvity Inc Azioni (RVTY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.72%
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):